1.Hennekens CH. Update on aspirin in the
treatment and prevention of cardiovascular disease. Am J Manag Care. 2002;8:S691-700.
2.Antithrombotic Trialists' Collaboration.
Collaborative meta-analysis of randomised trials of antiplatelet
therapy for prevention of death, myocardial infarction, and stroke
in high risk patients. Bmj.
2002;324:71-86.
3.Levine GN, Ali MN, Schafer AI. Antithrombotic
therapy in patients with acute coronary syndromes. Archives of Internal Medicine. 2001;161:937-48.
4.Van_De_Graaff E, Steinhubl SR. Antiplatelet
medications and their indications in preventing and treating coronary
thrombosis. Annals of Medicine.
2000;32:561-71.
5.Sze PC, Reitman D, Pincus MM, Sacks HS,
Chalmers TC. Antiplatelet agents in the secondary prevention of
stroke: meta-analysis of the randomized control trials. Stroke. 1988;19:436-42.
6.van Gijn J. Aspirin: dose and indications
in modern stroke prevention. Neurol
Clin. 1992;10:193-207; discussion 208.
7.Johnson ES, Lanes SF, Wentworth CE, 3rd,
Satterfield MH, Abebe BL, Dicker LW. A metaregression analysis
of the dose-response effect of aspirin on stroke. Arch
Intern Med. 1999;159:1248-53.
9.Hebert PR, Hennekens CH. An overview of
the 4 randomized trials of aspirin therapy in the primary prevention
of vascular disease. Arch
Intern Med. 2000;160:3123-7.
10.Hart RG, Bailey RD. An assessment of guidelines
for prevention of ischemic stroke. Neurology. 2002;59:977-82.
11.Ferraris VA, Ferraris SP, Joseph O, Wehner
P, Mentzer RM, Jr. Aspirin and postoperative bleeding after coronary
artery bypass grafting. Ann
Surg. 2002;235:820-7.
12.Smith JB, Willis AL. Aspirin selectively
inhibits prostaglandin production in human platelets. Nat New Biol. 1971;231:235-237.
13.Stein PD, Dalen JE, Goldman S, Schwartz
L, Theroux P, Turpie AG. Antithrombotic therapy in patients with
saphenous vein and internal mammary artery bypass grafts. Chest.
1995;108:424S-430S.
14.Goldman S, Copeland J, Moritz T, Henderson
W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S. Long-term
graft patency (3 years) after coronary artery surgery. Effects
of aspirin: results of a VA Cooperative study. Circulation.
1994;89:1138-43.
15.van der Meer J, Hillege HL, Kootstra GJ,
Ascoop CA, Mulder BJ, Pfisterer M, van Gilst WH, Lie KI. Prevention
of one-year vein-graft occlusion after aortocoronary-bypass surgery:
a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole,
and oral anticoagulants. The CABADAS Research Group of the Interuniversity
Cardiology Institute of The Netherlands. Lancet.
1993;342:257-64.
16.Goldman S, Copeland J, Moritz T, Henderson
W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, et
al. Saphenous vein graft patency 1 year after coronary artery
bypass surgery and effects of antiplatelet therapy. Results of
a Veterans Administration Cooperative Study. Circulation.
1989;80:1190-7.
17.Sanz G, Pajaron A, Alegria E, Coello I,
Cardona M, Fournier JA, Gomez-Recio M, Ruano J, Hidalgo R, Medina
A, et al. Prevention of early aortocoronary bypass occlusion by
low-dose aspirin and dipyridamole. Grupo Espanol para el Seguimiento
del Injerto Coronario (GESIC). Circulation. 1990;82:765-73.
18.Mayer JE, Jr., Lindsay WG, Castaneda W,
Nicoloff DM. Influence of aspirin and dipyridamole on patency
of coronary artery bypass grafts. Ann
Thorac Surg. 1981;31:204-10.
19.Jenicek M. Foundations of evidence-based medicine. New York: Parthenon Pub. Group;
2002.
20.Roth GJ, Stanford N, Majerus PW. Acetylation
of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073-6.
21.Smith WL, Garavito RM, DeWitt DL. Prostaglandin
endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157-33160.
22.Patrono C. Pharmacology of Antiplatelet
Agents. In: Loscalzo J, Schafer AI, eds. Thrombosis
and Hemorrhage. Baltimore, MD, USA: Williams & Wilkins;
1998:Chapter 54: pp. 1181-1192.
23.Patrono C, Coller B, Dalen JE, FitzGerald
GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs :
the relationships among dose, effectiveness, and side effects.
Chest. 2001;119:39S-63S.
24.Hornick P, George A. Blood contact activation:
pathophysiological effects and therapeutic approaches. Perfusion. 1996;11:3-19.
25.Mangano DT. Aspirin and mortality from coronary
bypass surgery. N Engl J
Med. 2002;347:1309-17.
26.Goldman S, Copeland J, Moritz T, Henderson
W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S. Internal
mammary artery and saphenous vein graft patency. Effects of aspirin.
Circulation. 1990;82:IV237-42.
27.Stein PD, Dalen JE, Goldman S, Theroux P.
Antithrombotic therapy in patients with saphenous vein and internal
mammary artery bypass grafts. Chest.
1998;114:658S-665S.
28.Musleh G, Dunning J. Does aspirin 6 h after
coronary artery bypass grafting optimise graft patency? Interactive Cardiovascular and Thoracic Surgery.
2003;2:413-415.
29.Dunning J, Satish D. What is the optimal
dose of aspirin after discharge following coronary bypass surgery.
Interactive Cardiovascular and Thoracic Surgery.
2003;2:427-430.
30.Ho WK, Hankey GJ, Eikelboom JW. Prevention
of coronary heart disease with aspirin and clopidogrel: efficacy,
safety, costs and cost-effectiveness. Expert
Opin Pharmacother. 2004;5:493-503.
31.Williams A, Hennekens CH. The role of aspirin
in cardiovascular diseases--forgotten benefits? Expert Opin Pharmacother. 2004;5:109-15.
32.Heidenreich PA, McClellan M. Trends in treatment
and outcomes for acute myocardial infarction: 1975-1995. Am J Med. 2001;110:165-74.
33.Rapaport E, Gheorghiade M. Pharmacologic
therapies after myocardial infarction. Am
J Med. 1996;101:4A61S-69S; discussion 4A69S-70S.
34.Braunwald E, Antman EM, Beasley JW, Califf
RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith
J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, 3rd, Steward DE,
Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos
G, Hiratzka LF, Jacobs AK, Smith SC, Jr. ACC/AHA 2002 guideline
update for the management of patients with unstable angina and
non-ST-segment elevation myocardial infarction--summary article:
a report of the American College of Cardiology/American Heart
Association task force on practice guidelines (Committee on the
Management of Patients With Unstable Angina). J
Am Coll Cardiol. 2002;40:1366-74.
35.Choussat R, Attali P. [Use of heparin in
unstable angina and non-Q-wave infarction]. Arch
Mal Coeur Vaiss. 2001;94:62-70.
36.Johnson WC, Williford WO. Benefits, morbidity,
and mortality associated with long-term administration of oral
anticoagulant therapy to patients with peripheral arterial bypass
procedures: a prospective randomized study. J
Vasc Surg. 2002;35:413-21.
37.Fihn SD, Williams SV, Daley J, Gibbons RJ.
Guidelines for the management of patients with chronic stable
angina: treatment. Ann Intern
Med. 2001;135:616-32.
38.Cappelleri JC, Lau J, Kupelnick B, Chalmers
TC. Efficacy and safety of different aspirin dosages on vascular
diseases in high-risk patients. A metaregression analysis. Online J Curr Clin Trials. 1995;Doc No 174:[6442 words; 55 paragraphs].
39.Sethi GK, Copeland JG, Goldman S, Moritz
T, Zadina K, Henderson WG. Implications of preoperative administration
of aspirin in patients undergoing coronary artery bypass grafting.
Department of Veterans Affairs Cooperative Study on Antiplatelet
Therapy. J Am Coll Cardiol. 1990;15:15-20.
40.Goldman S, Copeland J, Moritz T, Henderson
W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, et
al. Improvement in early saphenous vein graft patency after coronary
artery bypass surgery with antiplatelet therapy: results of a
Veterans Administration Cooperative Study. Circulation.
1988;77:1324-32.
41.Kallis P, Tooze JA, Talbot S, Cowans D,
Bevan DH, Treasure T. Pre-operative aspirin decreases platelet
aggregation and increases post-operative blood loss--a prospective,
randomised, placebo controlled, double-blind clinical trial in
100 patients with chronic stable angina. European
Journal of Cardio-Thoracic Surgery. 1994;8:404-9.
42.Ferraris VA, Ferraris SP, Lough FC, Berry
WR. Preoperative aspirin ingestion increases operative blood loss
after coronary artery bypass grafting. Ann
Thorac Surg. 1988;45:71-74.
43.Taggart DP, Siddiqui A, Wheatley DJ. Low-dose
preoperative aspirin therapy, postoperative blood loss, and transfusion
requirements. Ann Thorac
Surg. 1990;50:424-8.
44.Collaborative meta-analysis of randomised
trials of antiplatelet therapy for prevention of death, myocardial
infarction, and stroke in high risk patients. Bmj.
2002;324:71-86.
45.Srinivasan AK, Grayson AD, Pullan DM, Fabri
BM, Dihmis WC. Effect of preoperative aspirin use in off-pump
coronary artery bypass operations. Ann
Thorac Surg. 2003;76:41-5.
46.Scott WJ, Kessler R, Wernly JA. Blood conservation
in cardiac surgery. Ann
Thorac Surg. 1990;50:843-851.
47.Ferraris V, Ferraris S. Limiting excessive
postoperative blood transfusion after cardiac procedures: A review.
Tex Heart Inst J. 1995:22(3) 216-230.
48.Spencer FA, Santopinto JJ, Gore JM, Goldberg
RJ, Fox KA, Moscucci M, White K, Gurfinkel EP. Impact of aspirin
on presentation and hospital outcomes in patients with acute coronary
syndromes (The Global Registry of Acute Coronary Events [GRACE]).
Am J Cardiol. 2002;90:1056-61.
49.Dacey LJ, Munoz JJ, Johnson ER, Leavitt
BJ, Maloney CT, Morton JR, Olmstead EM, Birkmeyer JD, O'Connor
GT. Effect of preoperative aspirin use on mortality in coronary
artery bypass grafting patients. Ann
Thorac Surg. 2000;70:1986-90.
50.Ferraris VA, Swanson E. Aspirin usage and
perioperative blood loss in patients undergoing unexpected operations.
Surg Gynecol Obstet. 1983;156:439--42.
51.Matsuzaki K, Matsui K, Haraguchi N, Nagano
I, Okabe H, Asou T. Ischemic heart attacks following cessation
of aspirin before coronary artery bypass surgery: A report of
two cases. Ann Thorac Cardiovasc Surg. 1999;5:121-2.
52.Matsuzaki K, Okabe H, Kajihara N, Haraguchi
N, Nagano I, Tatewaki H, Matsui K. [A prospective study on the
timing of discontinuation of aspirin before coronary artery bypass
grafting]. Nippon Kyobu Geka Gakkai Zasshi. 1997;45:1710-4.
53.Salvioni A, Perego GB, Marenzi G, Galli
S, Assanelli E, Guazzi MD. Platelet Activity in the Early Stage
of Acute Myocardial Infarction: Relation to Time of Presentation,
Treatment with Either Tissue Plasminogen Activator or Streptokinase
and Cyclooxygenase Inhibition. J Thromb Thrombolysis. 1998;5:65-71.
54.Pothula S, Sanchala VT, Nagappala B, Inchiosa
MA, Jr. The effect of preoperative antiplatelet/anticoagulant
prophylaxis on postoperative blood loss in cardiac surgery. Anesth Analg. 2004;98:4-10, table of contents.
55.Oler A, Whooley MA, Oler J, Grady D. Adding
heparin to aspirin reduces the incidence of myocardial infarction
and death in patients with unstable angina. A meta-analysis. Jama. 1996;276:811-5.
56.Cohen M, Adams PC, Parry G, Xiong J, Chamberlain
D, Wieczorek I, Fox KA, Chesebro JH, Strain J, Keller C, et al.
Combination antithrombotic therapy in unstable rest angina and
non-Q-wave infarction in nonprior aspirin users. Primary end points
analysis from the ATACS trial. Antithrombotic Therapy in Acute
Coronary Syndromes Research Group. Circulation. 1994;89:81-8.
57.Goodman SG, Fitchett D, Armstrong PW, Tan
M, Langer A. Randomized evaluation of the safety and efficacy
of enoxaparin versus unfractionated heparin in high-risk patients
with non-ST-segment elevation acute coronary syndromes receiving
the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation.
2003;107:238-44.
58.Massel D, Cruickshank MK. Enoxaparin in
acute coronary syndromes: evidence for superiority over placebo
or untreated control. Am
Heart J. 2002;143:748-52.
59.Eikelboom J, White H, Yusuf S. The evolving
role of direct thrombin inhibitors in acute coronary syndromes.
J Am Coll Cardiol. 2003;41:70S-78S.
61.Cohen M. Low molecular weight heparins in
the management of unstable angina/non-Q-wave myocardial infarction.
Semin Thromb Hemost. 1999;25 Suppl 3:113-21.
62.Le Nguyen MT, Spencer FA. Low molecular
weight heparin and unfractionated heparin in the early pharmacologic
management of acute coronary syndromes: a meta-analysis of randomized
clinical trials. J Thromb Thrombolysis. 2001;12:289-95.
63.Jones HU, Muhlestein JB, Jones KW, Bair
TL, Lavasani F, Sohrevardi M, Horne BD, Doty D, Lappe DL. Preoperative
use of enoxaparin compared with unfractionated heparin increases
the incidence of re-exploration for postoperative bleeding after
open-heart surgery in patients who present with an acute coronary
syndrome: clinical investigation and reports. Circulation.
2002;106:I19-22.
64.van Es RF, Jonker JJ, Verheugt FW, Deckers
JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes
(the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360:109-13.
65.Knottenbelt C, Brennan PJ, Meade TW. Antithrombotic
treatment and the incidence of angina pectoris. Arch Intern Med. 2002;162:881-6.
66.Doggrell SA. Warfarin and aspirin give more
benefit than aspirin alone but also more bleeding after myocardial
infarction. Expert Opin
Pharmacother. 2003;4:587-90.
67.Anand SS, Yusuf S. Oral anticoagulants in
patients with coronary artery disease. J
Am Coll Cardiol. 2003;41:62S-69S.
68.O'Connor CM, Gattis WA, Hellkamp AS, Langer
A, Larsen RL, Harrington RA, Berkowitz SD, O'Gara PT, Kopecky
SL, Gheorghiade M, Daly R, Califf RM, Fuster V. Comparison of
two aspirin doses on ischemic stroke in post-myocardial infarction
patients in the warfarin (Coumadin) Aspirin Reinfarction Study
(CARS). Am J Cardiol. 2001;88:541-6.
69.Fiore LD, Ezekowitz MD, Brophy MT, Lu D,
Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative
Studies Program Clinical Trial comparing combined warfarin and
aspirin with aspirin alone in survivors of acute myocardial infarction:
primary results of the CHAMP study. Circulation. 2002;105:557-63.
70.Huynh T, Theroux P, Bogaty P, Nasmith J,
Solymoss S. Aspirin, warfarin, or the combination for secondary
prevention of coronary events in patients with acute coronary
syndromes and prior coronary artery bypass surgery. Circulation.
2001;103:3069-74.
71.Hurlen M, Abdelnoor M, Smith P, Erikssen
J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction.
N Engl J Med. 2002;347:969-74.
72.Wiggins BS, Spinler S, Wittkowsky AK, Stringer
KA. Bivalirudin: a direct thrombin inhibitor for percutaneous
transluminal coronary angioplasty. Pharmacotherapy.
2002;22:1007-18.
73.Bott JN, Reddy K, Krick S. Bivalirudin use
in off-pump myocardial revascularization in patients with heparin-induced
thrombocytopenia [corrected]. Ann
Thorac Surg. 2003;76:273-5.
74.Liu H, Fleming N, Moore P. Anticoagulation
for patients with heparin-induced thrombocytopenia using recombinant
hirudin during cardiopulmonary bypass. J Clin Anesth. 2002:14(6) 452-455.
75.Cameron RJ. r-hirudin as anticoagulant for
cardiopulmonary bypass. Anaesth
Intensive Care. 2001;29:627-30.
76.Gurbel PA, O'Connor CM, Cummings CC, Serebruany
VL. Clopidogrel: the future choice for preventing platelet activation
during coronary stenting? Pharmacol
Res. 1999;40:107-11.
77.Bhatt DL, Chew DP, Hirsch AT, Ringleb PA,
Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in
patients with prior cardiac surgery. Circulation.
2001;103:363-8.
78.Lubbe DF, Berger PB. The thienopyridines.
J Interv Cardiol. 2002;15:85-93.
79.Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis
BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Effects
of aspirin dose when used alone or in combination with clopidogrel
in patients with acute coronary syndromes: observations from the
Clopidogrel in Unstable angina to prevent Recurrent Events (CURE)
study. Circulation. 2003;108:1682-7.
80.Dyke C, Bhatia D. Inhibitors of the platelet
receptor glycoprotein IIb-IIIa and complications during percutaneous
coronary revascularization. Management strategies for the cardiac
surgeon. J Cardiovasc Surg (Torino). 1999;40:505-16.
81.Pang JT, Fort S, Della Siega A, Cohen EA.
Emergency coronary artery bypass surgery in the era of glycoprotein
IIb/IIIa receptor antagonist use. J
Card Surg. 2002;17:425-31.
82.Lee LY, DeBois W, Krieger KH, Girardi LN,
Russo L, McVey J, Ko W, Altorki NK, Brodman RA, Isom OW. The effects
of platelet inhibitors on blood use in cardiac surgery. Perfusion. 2002;17:33-7.
83.Silvestry SC, Smith PK. Current status of
cardiac surgery in the abciximab-treated patient. Ann Thorac Surg. 2000;70:S12-9.
84.Lemmer JH, Jr. Clinical experience in coronary
bypass surgery for abciximab-treated patients. Ann Thorac Surg. 2000;70:S33-7.
85.Kleiman NS. A risk-benefit assessment of
abciximab in angioplasty. Drug
Saf. 1999;20:43-57.
86.Dyke CM, Bhatia D, Lorenz TJ, Marso SP,
Tardiff BE, Hogeboom C, Harrington RA. Immediate coronary artery
bypass surgery after platelet inhibition with eptifibatide: results
from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina:
Receptor Suppression Using Integrelin Therapy. Ann
Thorac Surg. 2000;70:866-71; discussion 871-2.
87.Lemmer JH, Jr., Metzdorff MT, Krause AH,
Jr., Martin MA, Okies JE, Hill JG. Emergency coronary artery bypass
graft surgery in abciximab-treated patients. Ann
Thorac Surg. 2000;69:90-5.
89.Bizzarri F, Scolletta S, Tucci E, Lucidi
M, Davoli G, Toscano T, Neri E, Muzzi L, Frati G. Perioperative
use of tirofiban hydrochloride (Aggrastat) does not increase surgical
bleeding after emergency or urgent coronary artery bypass grafting.
J Thorac Cardiovasc Surg. 2001;122:1181-5.
90.Kawasaki T, Ozeki Y, Igawa T, Kambayashi
J. Increased platelet sensitivity to collagen in individuals resistant
to low-dose aspirin. Stroke.
2000;31:591-5.
91.Helgason CM, Bolin KM, Hoff JA, Winkler
SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance
in persons with previous ischemic stroke. Stroke.
1994;25:2331-6.
92.Gum PA, Kottke-Marchant K, Welsh PA, White
J, Topol EJ. A prospective, blinded determination of the natural
history of aspirin resistance among stable patients with cardiovascular
disease. J Am Coll Cardiol. 2003;41:961-5.
93.Andersen K, Hurlen M, Arnesen H, Seljeflot
I. Aspirin non-responsiveness as measured by PFA-100 in patients
with coronary artery disease. Thromb
Res. 2002;108:37-42.
94.Zimmermann N, Wenk A, Kim U, Kienzle P,
Weber AA, Gams E, Schror K, Hohlfeld T. Functional and biochemical
evaluation of platelet aspirin resistance after coronary artery
bypass surgery. Circulation. 2003;108:542-7.
95.Quinn MJ, Topol EJ. Common variations in
platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics. 2001;2:341-52.
96.Macchi L, Christiaens L, Brabant S, Sorel
N, Ragot S, Allal J, Mauco G, Brizard A. Resistance in vitro to
low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism
but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms.
J Am Coll Cardiol. 2003;42:1115-9.
98.Cerletti C, Dell'Elba G, Manarini S, Pecce
R, Di Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G.
Pharmacokinetic and pharmacodynamic differences between two low
dosages of aspirin may affect therapeutic outcomes. Clin
Pharmacokinet. 2003;42:1059-70.
99.Hundal RS, Petersen KF, Mayerson AB, Randhawa
PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose
aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109:1321-6.
100.Barragan P, Bouvier JL, Roquebert PO, Macaluso
G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler
M. Resistance to thienopyridines: clinical detection of coronary
stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein
phosphorylation. Catheter Cardiovasc Interv. 2003;59:295-302.
101.Kaplan S, Kaplan A, Marcoe K, Sauvage LR.
Ticlopidine, Alka-Seltzer, or a combination of citric acid with
aspirin: effects on platelet aggregation in individuals with an
insufficient response to aspirin alone. Clin
Appl Thromb Hemost. 2000;6:222-5.
102.Fiore LD, Brophy MT, Lopez A, Janson P, Deykin
D. The bleeding time response to aspirin. Identifying the hyperresponder.
Am J Clin Pathol. 1990;94:292-296.
103.Ferraris VA, Gildengorin V. Predictors of
excessive blood use after coronary artery bypass grafting. A multivariate
analysis [see comments]. J
Thorac Cardiovasc Surg. 1989;98:492-497.
104.Karkouti K, Cohen MM, McCluskey SA, Sher GD.
A multivariable model for predicting the need for blood transfusion
in patients undergoing first-time elective coronary bypass graft
surgery. Transfusion. 2001;41:1193-203.
105.Tempe D, Bajwa R, Cooper A, Nag B, Tomar AS,
Khanna SK, Satsangi DK, Gupta BK, Nigam M, Lall NG. Blood conservation
in small adults undergoing valve surgery. J
Cardiothorac Vasc Anesth. 1996;10:502-6.
106.Magovern JA, Sakert T, Benckart DH, Burkholder
JA, Liebler GA, Magovern GJ, Sr., Magovern GJ, Jr. A model for
predicting transfusion after coronary artery bypass grafting.
Ann Thorac Surg. 1996;61:27-32.
107.Kabakus N, Yilmaz B, Caliskan U. Investigation
of platelet aggregation by impedance and optic methods in children
with iron deficiency anaemia. Haematologia
(Budap). 2000;30:107-15.
108.Nilsson IM, Magnusson S, Borchgrevink C. The
Duke and Ivy Methods for Determination of the Bleeding Time. Thromb Diath Haemorrh. 1963;10:223-34.
109.Wisloff F, Godal HC. Prolonged bleeding time
with adequate platelet count in hospital patients. Scand J Haematol. 1981;27:45-50.
110.Castaman G, Federici AB, Rodeghiero F, Mannucci
PM. Von Willebrand's disease in the year 2003: towards the complete
identification of gene defects for correct diagnosis and treatment.
Haematologica. 2003;88:94-108.
111.Bellucci S, Caen J. Molecular basis of Glanzmann's
Thrombasthenia and current strategies in treatment. Blood Rev. 2002;16:193-202.
112.Badhe BA, Jayanthi S, Datta T. Clinical spectrum
of Glanzmann's thrombasthenia. Indian
J Pathol Microbiol. 2000;43:297-302.
113.Rand ML, Dean JA. Platelet function in autoimmune
(idiopathic) thrombocytopenic purpura. Acta Paediatr Suppl. 1998;424:57-60.
114.Kenny D, Morateck PA, Gill JC, Montgomery
RR. The critical interaction of glycoprotein (GP) IBbeta with
GPIX-a genetic cause of Bernard-Soulier syndrome. Blood.
1999;93:2968-75.
115.Jeter EK, Scott A, Kizer J, Lazarchick J.
Impaired platelet function associated with parenteral nafcillin.
Ann Clin Lab Sci. 1990;20:79-84.
116.McGill N, O'Shaughnessy D, Pickering R, Herbertson
M, Gill R. Mechanical methods of reducing blood transfusion in
cardiac surgery: randomised controlled trial. Bmj. 2002;324:1299.
117.Groom RC. High or low hematocrits during cardiopulmonary
bypass for patients undergoing coronary artery bypass graft surgery?
An evidence-based approach to the question. Perfusion. 2002;17:99-102.
118.Helm RE, Rosengart TK, Gomez M, Klemperer
JD, DeBois WJ, Velasco F, Gold JP, Altorki NK, Lang S, Thomas
S, Isom OW, Krieger KH. Comprehensive multimodality blood conservation:
100 consecutive CABG operations without transfusion. Ann
Thorac Surg. 1998;65:125-36.
119.Rosengart TK, Helm RE, DeBois WJ, Garcia N,
Krieger KH, Isom OW. Open heart operations without transfusion
using a multimodality blood conservation strategy in 50 Jehovah's
Witness patients: implications for a "bloodless" surgical
technique. J Am Coll Surg. 1997;184:618-29.
120.Jones JW, Rawitscher RE, McLean TR, Beall
AC, Jr., Thornby JI. Benefit from combining blood conservation
measures in cardiac operations. Ann
Thorac Surg. 1991;51:541-4; discussion 545-6.
122.Alvarez J, Jackson L, Chatwin C, Smolich J.
Low-dose postoperative aprotinin reduces mediastinal drainage
and blood product use in patients undergoing primary coronary
artery bypass grafting who are taking aspirin: A prospective,
randomized, double-blind, placebo-controlled trial. J
Thorac Cardiovasc Surg. 2001:122(3) 457-463.
123.Moran SV, Lema G, Medel J, Irarrazaval MJ,
Zalaquett R, Garayar B, Flaskamp R. Comparison of two doses of
aprotinin in patients receiving aspirin before coronary bypass
surgery. Perfusion. 2000;15:105-10.
124.Haddad R, Kesrouani C, Nasr W. Low-dose aprotinin
in cardiac operations. J
Med Liban. 2000;48:157-60.
125.Bidstrup BP, Hunt BJ, Sheikh S, Parratt RN,
Bidstrup JM, Sapsford RN. Amelioration of the bleeding tendency
of preoperative aspirin after aortocoronary bypass grafting. Ann Thorac Surg. 2000;69:541-7.
126.Bernet F, Carrel T, Marbet G, Skarvan K, Stulz
P. Reduction of blood loss and transfusion requirements after
coronary artery bypass grafting: Similar efficacy of tranexamic
acid and aprotinin in aspirin-treated patients. J
Card Surg. 1999:14(2) 92-97.
127.Klein M, Keith PR, Dauben HP, Schulte HD,
Beckmann H, Mayer G, Elert O, Gams E. Aprotinin counterbalances
an increased risk of peri-operative hemorrhage in CABG patients
pre-treated with Aspirin. European Journal of Cardio-Thoracic Surgery.
1998;14:360-6.
128.Ivert T, Intonti M, Stain-Malmgren R, Dumitrescu
A, Blomback M. Effects of aprotinin during cardiopulmonary bypass
in patients treated with acetylsalicylic acid. Scand
Cardiovasc J. 1998;32:289-95.
129.Tabuchi N, Huet RC, Sturk A, Eijsman L, Wildevuur
CR. Aprotinin preserves hemostasis in aspirin-treated patients
undergoing cardiopulmonary bypass. Ann
Thorac Surg. 1994;58:1036--9.
130.Alderman EL, Levy JH, Rich JB, Nili M, Vidne
B, Schaff H, Uretzky G, Pettersson G, Thiis JJ, Hantler CB, Chaitman
B, Nadel A. Analyses of coronary graft patency after aprotinin
use: results from the International Multicenter Aprotinin Graft
Patency Experience (IMAGE) trial. J
Thorac Cardiovasc Surg. 1998;116:716-30.
131.Minohara S, Asada K, Kondo K, Tatsumi T, Hasegawa
S, Sawada Y, Morimoto T, Matsuyama N, Sasaki S. [Effect of aprotinin
on bleeding during and graft patency after coronary artery bypass
grafting]. Nippon Kyobu Geka Gakkai Zasshi. 1997;45:821-4.
132.Lass M, Simic O, Ostermeyer J. Re-graft patency
and clinical efficacy of aprotinin in elective bypass surgery.
Cardiovasc Surg. 1997;5:604-7.
133.Dobkowski WB, Murkin JM. A risk-benefit assessment
of aprotinin in cardiac surgical procedures. Drug Saf. 1998;18:21-41.
134.Cohen G, Ivanov J, Weisel RD, Rao V, Mohabeer
MK, Mickle DA. Aprotinin and dipyridamole for the safe reduction
of postoperative blood loss. Ann
Thorac Surg. 1998;65:674-83.
135.Jobes DR. Safety issues in heparin and protamine
administration for extracorporeal circulation. J Cardiothorac Vasc Anesth. 1998;12:17-20.
136.Laupacis A, Fergusson D. Drugs to minimize
perioperative blood loss in cardiac surgery: meta-analyses using
perioperative blood transfusion as the outcome. The International
Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth
Analg. 1997;85:1258-67.
137.Pleym H, Stenseth R, Wahba A, Bjella L, Karevold
A, Dale O. Single-dose tranexamic Acid reduces postoperative bleeding
after coronary surgery in patients treated with aspirin until
surgery. Anesth Analg. 2003;96:923-8.
138.Giordano GF, Goldman DS, Mammana RB, Marco
JD, Nestor JD, Raczkowski AR, Rivers SL, Sanderson RG, Strug BS,
Sandler SG. Intraoperative autotransfusion in cardiac operations.
Effect on intraoperative and postoperative transfusion requirements.
J Thorac Cardiovasc Surg.
1988;96:382-6.
139.Cordell AR, Lavender SW. An appraisal of blood
salvage techniques in vascular and cardiac operations. Ann Thorac Surg. 1981;31:421-5.
140.Keeling MM, Gray LA, Jr., Brink MA, Hillerich
VK, Bland KI. Intraoperative autotransfusion. Experience in 725
consecutive cases. Ann Surg.
1983;197:536-41.
141.Petry AF, Jost J, Sievers H. Reduction of
homologous blood requirements by blood-pooling at the onset of
cardiopulmonary bypass. J
Thorac Cardiovasc Surg. 1994;107:1210-4.
142.Nuttall GA, Erchul DT, Haight TJ, Ringhofer
SN, Miller TL, Oliver WC, Jr., Zehr KJ, Schroeder DR. A comparison
of bleeding and transfusion in patients who undergo coronary artery
bypass grafting via sternotomy with and without cardiopulmonary
bypass. J Cardiothorac Vasc Anesth. 2003;17:447-51.
143.Reston JT, Tregear SJ, Turkelson CM. Meta-analysis
of short-term and mid-term outcomes following off-pump coronary
artery bypass grafting. Ann
Thorac Surg. 2003;76:1510-5.
144.Petro KR, Dullum MK, Garcia JM, Pfister AJ,
Qazi AG, Boyce SW, Bafi AS, Stamou SC, Corso PJ. Minimally invasive
coronary revascularization in women: A safe approach for a high-risk
group. Heart Surg Forum. 2000;3:41-6.
145.Potger KC, McMillan D, Connolly T, Southwell
J, Dando H, O'Shaughnessy K. Coronary artery bypass grafting:
an off-pump versus on-pump review. J
Extra Corpor Technol. 2002;34:260-6.
146.Hawkins D, Pinckard RN, Farr RS. Acetylation
of human serum albumin by acetylsalicylic acid. Science. 1968;160:780-1.
147.Bjornsson TD, Schneider DE, Berger H. Aspirin
acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic
effect is independent of changes in plasminogen activator levels.
The Journal of Pharmacology and Experimental Therapeutics. 1989;250:154-61.
148.Moroz LA. Increased blood fibrinolytic activity
after aspirin ingestion. The
New England Journal of Medicine. 1977;296:525-9.
149.Green D, Davies RO, Holmes GI, Johnson C,
Kohl H, Reynolds N, Ts_ao C. Fibrinolytic activity after administration
of diflunisal and aspirin. A double-blind, randomized, placebo-controlled
clinical trial. Haemostasis.
1983;13:394-8.
150.Santos MT, Valles J, Aznar J, Marcus AJ, Broekman
MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet
reactivity. Reduction by aspirin. Circulation.
1997;95:63-8.
151.Grau AJ, Reiners S, Lichy C, Buggle F, Ruf
A. Platelet function under aspirin, clopidogrel, and both after
ischemic stroke: a case-crossover study. Stroke.
2003;34:849-54.
152.Malinin AI, Atar D, Callahan KP, McKenzie
ME, Serebruany VL. Effect of a single dose aspirin on platelets
in humans with multiple risk factors for coronary artery disease.
Eur J Pharmacol. 2003;462:139-43.
153.Jang IK, Fuster V. Antithrombotic therapy
in cardiology and cardiovascular surgery. In: Pifarre R, ed. Anticoagulation, Hemostasis and Blood Preservation
in Cardiovascular Surgery. Philadelphia, PA, USA: Hanley &
Belfus; 1993:95-110.
154.Castano E, Dalmau M, Marti M, Berrocal F,
Bartrons R, Gil J. Inhibition of DNA synthesis by aspirin in Swiss
3T3 fibroblasts. J Pharmacol
Exp Ther. 1997;280:366-72.
155.Farivar RS, Brecher P. Salicylate is a transcriptional
inhibitor of the inducible nitric oxide synthase in cultured cardiac
fibroblasts. J Biol Chem.
1996;271:31585-92.
156.Shi X, Ding M, Dong Z, Chen F, Ye J, Wang
S, Leonard SS, Castranova V, Vallyathan V. Antioxidant properties
of aspirin: characterization of the ability of aspirin to inhibit
silica-induced lipid peroxidation, DNA damage, NF-kappaB activation,
and TNF-alpha production. Mol Cell Biochem. 1999;199:93-102.
157.Sanchez de Miguel L, de Frutos T, Gonzalez-Fernandez
F, del Pozo V, Lahoz C, Jimenez A, Rico L, Garcia R, Aceituno
E, Millas I, Gomez J, Farre J, Casado S, Lopez-Farre A. Aspirin
inhibits inducible nitric oxide synthase expression and tumour
necrosis factor-alpha release by cultured smooth muscle cells.
Eur J Clin Invest. 1999;29:93-9.
158.Podhaisky HP, Abate A, Polte T, Oberle S,
Schroder H. Aspirin protects endothelial cells from oxidative
stress--possible synergism with vitamin E. FEBS
Lett. 1997;417:349-51.
160.Goldman S, Copeland J, Moritz T, Henderson
W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GV, Khuri S, et
al. Starting aspirin therapy after operation. Effects on early
graft patency. Department of Veterans Affairs Cooperative Study
Group. Circulation.
1991;84:520-6.
161.Michelson EL, Morganroth J, Torosian M, Mac
Vaugh H, 3rd. Relation of preoperative use of aspirin to increased
mediastinal blood loss after coronary artery bypass graft surgery.
J Thorac Cardiovasc Surg. 1978;76:694-7.
162.Torosian M, Michelson EL, Morganroth J, MacVaugh
H, 3rd. Aspirin- and coumadin-related bleeding after coronary-
artery bypass graft surgery. Ann
Intern Med. 1978;89:325-8.
163.Bashein G, Nessly ML, Rice AL, Counts RB,
Misbach GA. Preoperative aspirin therapy and reoperation for bleeding
after coronary artery bypass surgery. Archives
of Internal Medicine. 1991;151:89-93.
164.Reich DL, Patel GC, Vela-Cantos F, Bodian
C, Lansman S. Aspirin does not increase homologous blood requirements
in elective coronary bypass surgery. Anesth
Analg. 1994;79:4-8.
165.Karwande SV, Weksler BB, Gay WA, Subramanian
VA. Effect of preoperative antiplatelet drugs on vascular prostacyclin
synthesis. Annals of Thoracic
Surgery. 1987;43:318-22.
166.Tuman KJ, McCarthy RJ, O'Connor CJ, McCarthy
WE, Ivankovich AD. Aspirin does not increase allogeneic blood
transfusion in reoperative coronary artery surgery. Anesth Analg. 1996;83:1178-84.
167.Vuylsteke A, Oduro A, Cardan E, Latimer RD.
Effect of aspirin in coronary artery bypass grafting. Journal of Cardiothoracic and Vascular Anesthesia. 1997;11:831-4.
168.Ray JG, Deniz S, Olivieri A, Pollex E, Vermeulen
MJ, Alexander KS, Cain DJ, Cybulsky I, Hamielec CM. Increased
blood product use among coronary artery bypass patients prescribed
preoperative aspirin and clopidogrel. BMC
Cardiovasc Disord. 2003;3:3.
169.Schonberger JP, Bredee JJ, van Oeveren W,
van Zundert AA, Verkroost M, Terwoorst J, Bavinck JH, Berreklouw
E, Wildevuur CR. Preoperative therapy of low-dose aspirin in internal
mammary artery bypass operations with and without low-dose aprotinin.
J Thorac Cardiovasc Surg. 1993;106:262-7.
170.Rawitscher RE, Jones JW, McCoy TA, Lindsley
DA. A prospective study of aspirin's effect on red blood cell
loss in cardiac surgery. J
Cardiovasc Surg (Torino). 1991;32:1-7.
171.Bjessmo S, Ivert T. Blood loss after coronary
artery bypass surgery: Relations to patient variables and antithrombotic
treatment. Scand Cardiovasc
J. 2000:34(4) 438-445.
172.Hall TS, Sines JC, Spotnitz AJ. Hemorrhage
related reexploration following open heart surgery: the impact
of pre-operative and post-operative coagulation testing. Cardiovasc
Surg. 2002;10:146-53.
173.McCusker K, Lee S. Post cardiopulmonary bypass
bleeding: an introductory review. Journal
of Extra Corporeal Technology. 1999;31:23-36.
174.Skubas NJ, Despotis GJ, Vlasnic JJ, Moon MR.
Preoperative use of enoxaparin and tirofiban: possible association
with increased bleeding postbypass. Anesthesiology.
1999;91:869-72.
175.Kincaid EH, Monroe ML, Saliba DL, Kon ND,
Byerly WG, Reichert MG. Effects of preoperative enoxaparin versus
unfractionated heparin on bleeding indices in patients undergoing
coronary artery bypass grafting. Ann
Thorac Surg. 2003;76:124-8; discussion 128.
176.Medalion B, Frenkel G, Patachenko P, Hauptman
E, Sasson L, Schachner A. Preoperative use of enoxaparin is not
a risk factor for postoperative bleeding after coronary artery
bypass surgery. J Thorac Cardiovasc Surg. 2003;126:1875-9.
177.Berkowitz SD, Stinnett S, Cohen M, Fromell
GJ, Bigonzi F. Prospective comparison of hemorrhagic complications
after treatment with enoxaparin versus unfractionated heparin
for unstable angina pectoris or non-ST-segment elevation acute
myocardial infarction. Am J Cardiol. 2001;88:1230-4.
178.Clark SC, Vitale N, Zacharias J, Forty J.
Effect of low molecular weight heparin (fragmin) on bleeding after
cardiac surgery. Ann Thorac
Surg. 2000;69:762-4; discussion 764-5.
179.Morris CD, Vega JD, Levy JH, Buist NN, Smith
AL, Despotis GJ, Kanter KR. Warfarin therapy does not increase
bleeding in patients undergoing heart transplantation. Ann Thorac Surg. 2001;72:714-8.
180.Randomised double-blind trial of fixed low-dose
warfarin with aspirin after myocardial infarction. Coumadin Aspirin
Reinfarction Study (CARS) Investigators. Lancet.
1997;350:389-96.
181.Bui JD, Despotis GD, Trulock EP, Patterson
GA, Goodnough LT. Fatal thrombosis after administration of activated
prothrombin complex concentrates in a patient supported by extracorporeal
membrane oxygenation who had received activated recombinant factor
VII. J Thorac Cardiovasc Surg. 2002;124:852-4.
182.Gansera B, Schmidtler F, Spiliopoulos K, Angelis
I, Neumaier-Prauser P, Kemkes BM. Urgent or emergent coronary
revascularization using bilateral internal thoracic artery after
previous clopidogrel antiplatelet therapy. Thorac
Cardiovasc Surg. 2003;51:185-9.
184.Hongo RH, Ley J, Dick SE, Yee RR. The effect
of clopidogrel in combination with aspirin when given before coronary
artery bypass grafting. J
Am Coll Cardiol. 2002;40:231-7.
185.Yende S, Wunderink RG. Effect of clopidogrel
on bleeding after coronary artery bypass surgery. Crit Care Med. 2001;29:2271-5.
186.Miyagi Y, Yamauchi S, Suzuki S, Kitagawa A,
Masaki Y, Gomibuchi M, Tanaka S. Investigation of coronary artery
bypass grafting for a patient with myelodysplastic syndrome. Ann Thorac Cardiovasc Surg. 2001;7:250-3.
187.Christiansen S, Rotker J, Roeder N, Jahn UR,
Stypmann J, Scheld HH, Schmid C. Are patients with Werlhof's disease
at increased risk for bleeding complications when undergoing cardiac
surgery? Eur J Cardiothorac Surg. 2000;18:353-6.
189.Boccara F, Michel M, Hermine O, Kaplan C,
Aumont MC. [Thrombocytopenia after cardiac surgery due to anti-platelet
allo-immunization. Apropos of a case]. Arch
Mal Coeur Vaiss. 1997;90:107-10.
190.Jubelirer SJ. Coronary artery bypass in two
patients with immune thrombocytopenic purpura without preoperative
splenectomy. W V Med J.
1992;88:510-1.
